BENSERAZIDE HYDROCHLORIDE,
Benserazide HCl,
14919-77-8,
Benzerazide hydrochloride,
2-amino-3-hydroxy-N'-(2,3,4-trihydroxybenzyl)propanehydrazide hydrochloride,
Benserazide (hydrochloride),
Ro 4-4602/001,
CCRIS 5092,
2'-(2,3,4-Trihydroxybenzyl)-DL-serinohydrazide monohydrochloride,
DL-SERINE 2,
EINECS 238-991-9,
DL-Serine 2-(2,3,4-trihydroxybenzyl)hydrazine hydrochloride,
MLS000028424,
14046-64-1,
CHEBI:31262,
MFCD00078571,
Ro-4-4602,
SMR000058421,
2-amino-3-hydroxy-N'-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide hydrochloride,
DSSTox_CID_25412,
DSSTox_RID_80862,
DSSTox_GSID_45412,
C10H16ClN3O5,
W-108090,
DL-Serine 2-(2,3,4-trihydroxybenzyl)hydrazide hydrochloride,
Serine, 2-(2,3,4-trihydroxybenzyl)hydrazide, monohydrochloride, DL-,
3-hydroxy-1-oxo-1-[2-(2,3,4-trihydroxybenzyl)hydrazinyl]propan-2-aminium chloride,
SR-01000003044,
27172-87-8,
Benserazide hydrochloride [JAN],
2-amino-3-hydroxy-N'-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide;hydrochloride,
Opera_ID_1594,
NCGC00016709-01,
Serazide;Ro 4-4602,
Madopa (Hoffmann-LaRoche),
AC1L1C8T,
CAS-14919-77-8,
MLS001148252,
MLS002222160,
C10H15N3O5.HCl,
SCHEMBL364720,
SPECTRUM1500137,
CHEMBL1255778,
DTXSID0045412,
HY-B0404A,
Benserazide hydrochloride (JP17),
Benserazide HCl (Ro 4-4602),
HMS1570L18,
HMS1920G05,
Pharmakon1600-01500137,
Benserazide-hydrochloride(Serazide),
BCP14068,
Tox21_110573,
Tox21_500233,
BG0103,
CB0168,
CCG-38998,
NSC755907,
s2453,
AKOS007930267,
Tox21_110573_1,
AC-6825,
AN-5849,
API0007085,
CS-2504,
H22B350,
LP00233,
NSC-755907,
KS-00000Y25,
NCGC00015163-09,
NCGC00093698-01,
NCGC00093698-02,
NCGC00093698-03,
NCGC00093698-04,
NCGC00093698-05,
NCGC00260918-01,
AK-77683,
AS-13683,
BC200991,
H794,
AB0013267,
AB2000568,
LS-145026,
B4108,
EU-0100233,
FT-0659734,
FT-0760799,
ST24039907,
SW196391-3,
B 7283,
D01653,
J10106,
K-4739,
Benserazide hydrochloride, >=98% (TLC), solid,
A808862,
I14-2800,
SR-01000003044-2,
SR-01000003044-8,
Benserazide hydrochloride, European Pharmacopoeia (EP) Reference Standard,
DL-Serine, 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide, monohydrochloride,
DL-Serine, 2-[(2,3,4-trihydroxyphenyl)methyl]hydrazide hydrochloride,
2-azanyl-3-oxidanyl-N'-[[2,3,4-tris(oxidanyl)phenyl]methyl]propanehydrazide hydrochloride,
Benserazide for peak identification, European Pharmacopoeia (EP) Reference Standard,
DL-Serine, 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide, monohydrochloride (9CI),
benserazide,
Serazide,
Benparizde,
UNII-B66E5RK36Q,
C10H15N3O5.ClH,
B66E5RK36Q,
Benserazide hydrochloride, 98% 1g,
CID26964,
Ro 4-4602,
C10-H15-N3-O5.Cl-H,
CS-O-11605,
(S)-2-Amino-3-hydroxy-N'-(2,3,4-trihydroxybenzyl)propanehydrazide hydrochloride,
dl-serine2-(2,3,4-trihydroxybenzyl)hydrazidehydrochloride,
DL-Serine, 2-[(2,3,4-trihydroxyphenyl)methyl]hydrazide, monohydrochloride,
Benserazide hydrochloride, 98%, peripherally acting DOPA decarboxylase inhibitor - 1G 1g,
322-35-0,